Jonathan R I Coleman1, Kathryn J Lester1,2, Susanna Roberts1, Robert Keers1,3, Sang Hyuck Lee1,4, Simone De Jong1,4, Héléna Gaspar1,4, Tobias Teismann5, André Wannemüller5,6, Silvia Schneider5, Peter Jöhren6, Jürgen Margraf5, Gerome Breen1,4, Thalia C Eley1,4. 1. a King's College London, Institute of Psychiatry, Psychology and Neuroscience, MRC Social, Genetic and Developmental Psychiatry (SGDP) Centre , London , UK. 2. b School of Psychology, University of Sussex , UK. 3. c School of Biological and Chemical Sciences, Queen Mary University of London , London , UK. 4. d National Institute for Health Research Biomedical Research Centre, South London and Maudsley National Health Service Trust , London, UK. 5. e Mental Health Research and Treatment Center, Ruhr-Universität Bochum, Bochum , Germany. 6. f Dental Clinic Bochum , Bochum , Germany.
Abstract
OBJECTIVES:Exposure-based cognitive behavioural therapy (eCBT) is an effective treatment for anxiety disorders. Response varies between individuals. Gene expression integrates genetic and environmental influences. We analysed the effect of gene expression and genetic markers separately and together on treatment response. METHODS:Adult participants (n ≤ 181) diagnosed with panic disorder or a specific phobia underwenteCBT as part of standard care. Percentage decrease in the Clinical Global Impression severity rating was assessed across treatment, and between baseline and a 6-month follow-up. Associations with treatment response were assessed using expression data from 3,233 probes, and expression profiles clustered in a data- and literature-driven manner. A total of 3,343,497 genetic variants were used to predict treatment response alone and combined in polygenic risk scores. Genotype and expression data were combined in expression quantitative trait loci (eQTL) analyses. RESULTS:Expression levels were not associated with either treatment phenotype in any analysis. A total of 1,492 eQTLs were identified with q < 0.05, but interactions between genetic variants and treatment response did not affect expression levels significantly. Genetic variants did not significantly predict treatment response alone or in polygenic risk scores. CONCLUSIONS: We assessed gene expression alone and alongside genetic variants. No associations with treatment outcome were identified. Future studies require larger sample sizes to discover associations.
RCT Entities:
OBJECTIVES: Exposure-based cognitive behavioural therapy (eCBT) is an effective treatment for anxiety disorders. Response varies between individuals. Gene expression integrates genetic and environmental influences. We analysed the effect of gene expression and genetic markers separately and together on treatment response. METHODS: Adult participants (n ≤ 181) diagnosed with panic disorder or a specific phobia underwent eCBT as part of standard care. Percentage decrease in the Clinical Global Impression severity rating was assessed across treatment, and between baseline and a 6-month follow-up. Associations with treatment response were assessed using expression data from 3,233 probes, and expression profiles clustered in a data- and literature-driven manner. A total of 3,343,497 genetic variants were used to predict treatment response alone and combined in polygenic risk scores. Genotype and expression data were combined in expression quantitative trait loci (eQTL) analyses. RESULTS: Expression levels were not associated with either treatment phenotype in any analysis. A total of 1,492 eQTLs were identified with q < 0.05, but interactions between genetic variants and treatment response did not affect expression levels significantly. Genetic variants did not significantly predict treatment response alone or in polygenic risk scores. CONCLUSIONS: We assessed gene expression alone and alongside genetic variants. No associations with treatment outcome were identified. Future studies require larger sample sizes to discover associations.
Authors: Christopher Rayner; Jonathan R I Coleman; Kirstin L Purves; John Hodsoll; Kimberley Goldsmith; Georg W Alpers; Evelyn Andersson; Volker Arolt; Julia Boberg; Susan Bögels; Cathy Creswell; Peter Cooper; Charles Curtis; Jürgen Deckert; Katharina Domschke; Samir El Alaoui; Lydia Fehm; Thomas Fydrich; Alexander L Gerlach; Anja Grocholewski; Kurt Hahlweg; Alfons Hamm; Erik Hedman; Einar R Heiervang; Jennifer L Hudson; Peter Jöhren; Robert Keers; Tilo Kircher; Thomas Lang; Catharina Lavebratt; Sang-Hyuck Lee; Kathryn J Lester; Nils Lindefors; Jürgen Margraf; Maaike Nauta; Christiane A Pané-Farré; Paul Pauli; Ronald M Rapee; Andreas Reif; Winfried Rief; Susanna Roberts; Martin Schalling; Silvia Schneider; Wendy K Silverman; Andreas Ströhle; Tobias Teismann; Mikael Thastum; Andre Wannemüller; Heike Weber; Hans-Ulrich Wittchen; Christiane Wolf; Christian Rück; Gerome Breen; Thalia C Eley Journal: Transl Psychiatry Date: 2019-05-23 Impact factor: 6.222
Authors: Susanna Roberts; Robert Keers; Gerome Breen; Jonathan R I Coleman; Peter Jöhren; Agnieszka Kepa; Kathryn J Lester; Jürgen Margraf; Silvia Scheider; Tobias Teismann; André Wannemüller; Thalia C Eley; Chloe C Y Wong Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2018-10-18 Impact factor: 3.568
Authors: S Roberts; C C Y Wong; G Breen; J R I Coleman; S De Jong; P Jöhren; R Keers; C Curtis; S H Lee; J Margraf; S Schneider; T Teismann; A Wannemüller; K J Lester; T C Eley Journal: Transl Psychiatry Date: 2017-08-29 Impact factor: 6.222
Authors: Natalia Rodriguez; Albert Martinez-Pinteño; Ana Blázquez; Ana Encarnación Ortiz; Elena Moreno; Patricia Gassó; Amalia Lafuente; Luisa Lazaro; Sergi Mas Journal: Pharmgenomics Pers Med Date: 2021-06-29